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The myelodysplastic syndromes are a group of clonal hematopoietic stem cell diseases characterized by cytopenia(s),
dysplasia in one or more cell lineages and increased risk of evolution to acute myeloid leukemia (AML). Recent advances
in immunophenotyping of hematopoietic progenitor and maturing cells in dysplastic bone marrow point to a useful role
for multiparameter flow cytometry (FCM) in the diagnosis and prognostication of myelodysplastic syndromes. In March
2008, representatives from 18 European institutes participated in a European LeukemiaNet (ELN) workshop held in
Amsterdam as a first step towards standardization of FCM in myelodysplastic syndromes. Consensus was reached
regarding standard methods for cell sampling, handling and processing. The group also defined minimal combinations of
antibodies to analyze aberrant immunophenotypes and thus dysplasia. Examples are altered numbers of CD34+ precur-
sors, aberrant expression of markers on myeloblasts, maturing myeloid cells, monocytes or erythroid precursors and the
expression of lineage infidelity markers. When applied in practice, aberrant FCM patterns correlate well with morphol-
ogy, the subclassification of myelodysplastic syndromes, and prognostic scoring systems. However, the group also con-
cluded that despite strong evidence for an impact of FCM in myelodysplastic syndromes, further (prospective) validation
of markers and immunophenotypic patterns are required against control patient groups as well as further standardiza-
tion in multi-center studies. Standardization of FCM in myelodysplastic syndromes may thus contribute to improved
diagnosis and prognostication of myelodysplastic syndromes in the future.
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Introduction
Myelodysplastic syndromes (MDS) are a heteroge-
neous group of myeloid neoplasms characterized by
dysplastic features of erythroid and/or myeloid and/or
megakaryocytic lineages, a varying percentage of blast
cells, progressive bone marrow failure and enhanced risk
to evolve towards acute myeloid leukemia.1 In 2007
refined definitions and standards in the diagnosis of
MDS were reported.2 Using the proposed minimal diag-
nostic criteria, additional tests (co-criteria) can be applied
and may help to decide whether the patient has a
myeloid neoplasm with bone marrow failure resembling
(or highly suspicious of) MDS. This is of importance par-
ticularly in patients with only mild or absent dysplasia
but otherwise typical MDS-related clinical findings (e.g.
transfusion-dependent macrocytic anemia). Flow cytom-
etry (FCM) analysis of bone marrow cells has been intro-
duced as an important co-criterion.2 In March 2008, the
first International Workshop on Standardization of FCM
in MDS convened in Amsterdam. Thirty participants
from 18 institutes throughout Europe working within
the European LeukemiaNet (ELN) and 3 experts from
outside Europe (USA and Japan) joined this meeting. The
group has a vast experience of integrating FCM in the
work-up of patients with suspected MDS patients.3
Recent studies conducted by members of the consor-
tium indicate that the FCM approach is reproducible and
can identify specific aberrations on both the immature
and mature compartments among different bone mar-
row hematopoietic cell lineages. A more general applica-
tion of FCM in the diagnosis and prognostication of
MDS, especially in low and intermediate-I risk MDS, has
been hampered by the lack of standardization of meth-
ods and interpretation of data obtained by FCM.
The major goals of the working conference were: (a)
to define the role of FCM in diagnosis and prognostica-
tion of MDS related to the currently validated FAB,
WHO, IPSS and WPSS systems; (b) to discuss the opti-
mal methods of sample processing and handling; (c) to
propose a consensual minimal set of monoclonal anti-
bodies useful to assess dysplasia by FCM of bone mar-
row cells in known or suspected MDS; (d) to consider
the specificity of FCM analysis of MDS related to a
series of other hematologic benign and malignant dis-
eases and (e) to suggest additional recommendations on
FCM to further optimize analysis for future directions.
Role of flow cytometry in myelodysplastic 
syndromes in relation to diagnosis, prognosis
and disease monitoring
Flow cytometry in myelodysplastic syndromes 
in relation to minimal diagnostic criteria 
and WHO classification
The previous use of FCM in MDS has been primarily
restricted to the characterization of blast cells in second-
ary acute leukemia following MDS. However, it has
been shown that myeloid and monocytic dyspoiesis
identified as phenotypic abnormalities by FCM in MDS
correlates with the International Prognostic Scoring
System (IPSS), the WHO-adjusted prognostic scoring
system (WPSS), transfusion dependency, and time-to-
progression to advanced MDS/AML, as well as with out-
come after hematopoietic stem cell transplantation.4-6 In
addition, immunophenotypic aberrancies of myelo-
blasts, e.g. over- or decreased expression of common
myeloid antigens or expression of lineage infidelity
markers, may have independent prognostic impact even
if the percentage of blasts in the bone marrow is lower
than 5%.4-7 Aberrant expression of certain antigens (CD7
and/or TdT) on myeloblast cells has been shown to cor-
relate with poor clinical outcome.6,8,9 These studies indi-
cate that FCM shows promise in contributing signifi-
cantly to the diagnosis and prognosis of MDS.
The WHO classification clearly distinguishes between
patients with refractory cytopenia exhibiting unilineage
dysplasia (RCUD) and refractory anemia with/without
ring sideroblasts (RA+/-RS) from those with dysplasia in
two or three cell lineages (refractory cytopenia with
multilineage dysplasia, RCMD) with respect to overall
survival (OS) and leukemia-free survival.1 Patients with
RCMD+/-RS show a shorter overall survival (OS) as
compared to RA+/-RS.10 It is of interest that the life
expectancy of patients with unilineage dysplasia, e.g.,
RA above 70 years of age, does not differ from that of
the normal population.10 Therefore, a clear distinction
between unilineage RA+/-RS and multi-lineage
RCMD+/-RS is of importance for disease management.
Flow cytometry might help to distinguish true RA from
RCMD by identifying RA with immunophenotypic
abnormalities in multiple compartments from RA with
normal immunophenotype. Recently, patients with
multi-lineage immunophenotypic aberrations were
identified by FCM among cases displaying unilineage
morphological dysplasia according to the WHO (RA and
MDS-U).6,11
Flow cytometry may add significantly to the diagnosis
of new subgroups of refractory cytopenias as defined by
the new WHO classification of 2008, e.g. refractory ane-
mia (RA), refractory neutropenia (RN) and refractory
thrombocytopenia (RT), which will be studied prospec-
tively. Also, the assessment of FCM aberrancies (qualita-
tive and quantitative) on blasts may have additional
diagnostic and prognostic impact in patients with excess
of blasts. Therefore, in refractory anemia with excess
blasts (RAEB-1 and RAEB-2), the extent of abnormalities
in blast populations, as well as additional FCM aberran-
cies in the more mature myeloid or monocyte compart-
ments, might be of importance. 
Moreover, low-risk WPSS patients who are transfu-
sion-independent and have a normal karyotype may be
distinguished from patients with idiopathic cyto-
penia/anemia of undetermined significance (ICUS)
based on immunophenotypic abnormalities.2 In these
patients, FCM may help in reaching the conclusion that
the patient likely suffers from a clonal disease process
(e.g. MDS) rather than ICUS which includes cases of sus-
tained cytopenias (>6 months) in one or more myeloid
lineages (erythroid, neutrophil and megakaryocytic) that
do not meet the minimal criteria for MDS and cannot be
explained by any other hematologic or non-hematologic
Flow cytometry in MDS
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disease.2,12 In some of these patients, the type of cytope-
nia (e.g. transfusion-dependent macrocytic anemia) may
point to the potential existence of an underlying MDS or
a pre-MDS phase. It has been proposed that FCM con-
tributes significantly to diagnosis and may distinguish
early MDS from ICUS due to its accuracy in enumerating
blasts, to assess abnormalities in the blast population
(even <5%) and by documenting immunophenotypic
abnormalities in maturing myeloid cells. Finally, the
WHO classification separates MDS with isolated del(5q)
as a distinct entity since these patients are characterized
by specific morphological and clinical parameters and
have a very low risk of evolving to AML.13 Flow cytome-
try might help to identify 5q- patients with or without
additional immunophenotypic abnormalities. 
Flow cytometry in myelodysplastic syndromes 
in relation to risk assessment by cytogenetics,
genomics, IPSS and WPSS
The IPSS represents the benchmark for clinical trials
and the treatment-decision making processes in MDS.14
In addition, the effects of the validated IPSS variables
(morphological bone marrow blast cell percentage,
number of peripheral cytopenias and karyotype) within
WHO categories have been shown to correlate with
outcome in several studies.15-19 A major limitation of the
IPSS is that newly defined prognostic parameters have
not been included, e.g. LDH, bone marrow fibrosis, cir-
culating blasts (normal or aberrant), as well as data on
transfusion requirements. In addition, there is increas-
ing evidence to suggest that the IPSS-defined cytogenet-
ic subgroups should be reclassified.17,20 In that context,
FCM may also be of importance in those patients with
a normal karyotype and an equivocal morphology (e.g.
not fulfilling the minimal diagnostic criteria as discussed
above) and in patients with a normal karyotype but
with less than 20 metaphases analyzed with no proof of
clonality.21,22 Emerging evidence from single nucleotide
polymorphisms (SNP) array genotyping studies sug-
gests that clonal selection and expansion is present in
some cases where morphological evidence for MDS is
equivocal. Prospective studies will be required to deter-
mine whether conventional karyotyping, SNP kary-
otyping and FCM are able to further distinguish MDS
subgroups. First data are currently being reported on
microRNA expression profiling in MDS.23-29 Although
the WPSS provides a superior prognostic algorithm
compared to IPSS, FCM may further improve diagnosis
and prognostication. Prospective studies are now begin-
ning to further assess the relevance of WPSS and FCM
in MDS. Yet, the significance of morphological classifi-
cation and prognostic scoring systems in MDS is not
defined for patients treated with currently available
drugs and therefore may not adequately predict disease
outcome. Newly designed prospective studies are war-
ranted to include old and new methods, e.g. FCM, to
accurately investigate the prognostic significance.
Flow cytometry in monitoring treatment and disease
progression in myelodysplastic syndromes
Disease monitoring in MDS implies sequential analysis
of characteristic aberrancies. Once certain immuno-
phenotypic aberrancies are defined, patients can also be
monitored by FCM to determine disease progression
(increased abnormalities) or response to therapeutic
interventions. Preliminary studies indicate that MDS-
related FCM abnormalities in bone marrow cells are no
longer detectable or decrease in number in responding
patients when compared to pre-treatment results.30
Response to intensive therapy may lead to reconstitution
of normal cells after neoplastic cells have been eliminat-
ed which can be nicely demonstrated by FCM. A caveat
is that therapeutic drugs can alter aberrancies or even
introduce new ones. Stable FCM aberrancies during
treatment may spare patients long-term treatment with
ineffective drugs with potential toxicity. Flow cytometry
monitoring may be important especially when no other
disease parameters, such as molecular and cytogenetic
parameters, are available. Finally, FCM may contribute
significantly in those patients in complete remission (CR)
after induction therapy for AML with persistence of
cytopenias that suggest a pre-phase of MDS. The clinical
outcome of these patients is very poor.
Optimal methods for processing and
handling of samples for flow cytometry
in myelodysplastic syndromes
Published studies regarding the immunophenotypic
characteristics of erythroid, precursor and maturing
myeloid cells in MDS patients employed variable
methodologies and different reagents. In virtually all
studies, diverse panels of antibodies, different anticoagu-
lants, time to FCM, and storage/transport conditions
were used. Moreover, information about instrument set-
tings and quality control is usually limited. In previous
immunophenotypic studies of hematologic malignancies,
many of these variables have been shown to dramatical-
ly influence the results of FCM analysis.31 In MDS, such
technical issues are particularly relevant, since they can
affect the number of immunophenotypic abnormalities
detected and the magnitude of such abnormalities. Thus,
standardized application of FCM in the diagnosis and
monitoring of MDS requires a minimal variability intro-
duced by different sample processing, antibody combina-
tions, data acquisition and interpretation of data.
We documented the variations in these technical
parameters in 15 participating institutes through a sur-
vey of practice. A summary of the questionnaires (set
out in part in Tables 1-3) was a starting point of discus-
sions with the aim of reaching a consensus on how to
standardize these parameters. The final recommenda-
tions for the various steps involved in FCM in MDS are
discussed below.
Sample preparation, handling and processing
Samples
Analysis of FCM aberrancies in MDS should be per-
formed preferably in bone marrow samples; only sparse
data are available on FCM in MDS in peripheral blood
samples. Bone marrow aspirates should be collected
using either heparin or, less preferable, EDTA as antico-
agulant. Delayed processing of specimens collected in
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EDTA may influence the expression of certain antigens
such as CD10, CD11b, CD16 and CD64.11,32 Sample
processing should preferably be performed within 24 h
after aspiration. The sample should be stored at room
temperature until processed in the laboratory. Samples
processed at later time points may still be evaluable, but
extra controls should be included to evaluate the quali-
ty of the sample. Addition of glucose containing tissue
culture media (1:1) may be helpful in preserving cell via-
bility.
Red blood cell lysis
Flow cytometry in MDS mainly concerns analysis of
white blood cells and nucleated red blood cells. For lysis of
the non-nucleated red blood cells, ammonium chloride
(either home-made or commercially available) should be
used. The lysing solution should not contain a fixative,
since this may result in selective cell loss or may change
light scatter properties of the cells. Other (commercial)
lysing solutions, not containing a fixative, may be used
after parallel testing. The lysis of red blood cells is recom-
mended prior to antibody staining for two main reasons.
First, bulk-lysis will result in fully identical cell suspensions
in the separate analysis tubes, thereby facilitating compar-
ison between tubes. Second, this approach allows the use
of a fixed cell concentration for the stainings. Red blood
cell lysing can be performed by mixing a maximum of 3 ml
whole bone marrow with ammonium chloride (total vol-
ume: 50 mL); incubation for 10 min at room temperature
while mixing gently. Cells should be washed using phos-
phate buffered saline (PBS) with 0.5% bovine or human
serum albumin (hereafter referred to as washing buffer).
Centrifugation should be performed at 300g or less. If,
after washing, macroscopic evaluation shows that the cell
pellet still contains red blood cells, a second lysing step
may be performed. Otherwise, the cell pellet can be resus-
pended in washing buffer. The use of mononuclear cells
after density separation is not recommended due to selec-
tive loss of cells (particularly mature granulocytes). It
should be noted, however, that density separation may be
preferable for specific applications such as assessment of
the erythroid lineage.24
Antibody staining
Dilution of antibodies and washing of cells should be
performed using PBS/0.5% bovine or human serum
albumin. The addition of serum albumin prevents non-
specific binding of antibodies and therefore reduces
background staining. To assure sufficient and constant
numbers of analyzed cells, it is recommended to use
500,000 cells per tube. Optimally titrated antibodies
should be added to the cell suspension and after gently
mixing, cells should be incubated for 15 min at room
temperature in the dark. Special care should be taken if
tandem-fluorochromes are used, since these fluo-
rochromes may be highly sensitive to light exposure
(such as PE-Cy5, PE-Cy7, APC-H7 and HorizonTM V450
conjugates). It must also be pointed out that compensa-
tion settings frequently vary from batch to batch. After
incubation, cells should be washed at least once. In
addition to surface staining, intracellular staining may
be informative. If intracellular staining is performed,
the membrane-bound antigens should be stained first,
followed by fixation and permeabilization using well
evaluated commercial reagents and subsequent intra-
cellular staining and washing. Since many fixation and
permeabilization reagents may alter the light scatter
characteristics of the cells, it is not recommended to use
the scatter characteristics for identification and gating
of cells. In addition, since fixation and permeabilization
Flow cytometry in MDS
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Table 1. Parameters scored as aberrant in the immature compartment.
Myeloblasts %1 B cell progenitors %
Increased percentage2 91 Decreased number/percentage† 82
increased number/percentage 45
Abnormal granularity (SSC)2 73
Abnormal expression of CD452 100
Abnormal expression of CD13 100
Abnormal expression of CD33 100
Abnormal expression of CD342 91
Abnormal expression of CD1172 82
Expression of CD11b2 82
Expression of CD152 64
Abnormal expression of HLA-DR2 55
Expression of CD36 45
Abnormal expression of TdT 36
Expression of CD41/CD42b/CD61 36
Expression of CD38 27
Expression of CD4 18
Expression of lineage infidelity marker CD22 82
Expression of lineage infidelity marker CD52 82
Expression of lineage infidelity marker CD72 91
Expression of lineage infidelity marker CD192 91
Expression of lineage infidelity marker CD562 91
1percentage of survey participants who analyzed a given aberrancy; 2considered as relevant finding.
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may result in selective cell loss, this procedure should
not be used for enumeration of cell populations.
Cell fixation
To stabilize cell membranes, prevent possible dissocia-
tion of antibodies and reduce biohazard, it is recom-
mended to fix the cells after staining and washing.33
Commercially available 0.5% paraformaldehyde (PFA) in
PBS (pH 7.4) is recommended. Washed cells should be
resuspended in fixation buffer (PBS/0.5% PFA). Cells
should not be stored after this fixation step, but immedi-
ately processed for sample acquisition on the flow
cytometer. Of note, some of the newer tandem conju-
gates are subject to partial degradation when PFA is
added. To minimize variations in sample processing, the
use of automated sample preparation platforms would
be preferable. 
Instrument setup and data acquisition
The number of lasers, the number of detectors, the set-
up of the filters, and digital or analog data processing will
logically affect the number of antibodies and the types of
fluorochromes that can be assessed simultaneously and
will have significant impact on the fluorescent patterns
obtained. The flow cytometer should be set up and cali-
brated according to previously published recommenda-
tions.34 
Application of multiparameter flow cytometry
analysis in myelodysplastic syndromes
Application of FCM in the diagnosis, prognostication
and monitoring of MDS requires consensus on a minimal
panel of antibodies necessary to classify specific bone
marrow subpopulations, enumerating blast cells and
detecting immunophenotypic lineage-associated dyspla-
sia. The workshop participants agreed on the characteri-
zation of the immature blasts as well as the maturing
monocyte, myeloid and erythroid lineages. Analysis of
dysplasia of megakaryopoiesis is excluded since current
knowledge of dysplastic marker expression in this cell
type is limited. The same holds true for basophils,
eosinophils, dendritic cell populations and mast cells,
although one can expect that also these cells are some-
times involved in the neoplastic process and thus display
aberrant phenotypes in MDS.7,3
Table 3. Parameters scored as aberrant in the erythroid compart-
ment.
Erythroid cells %1
Increased percentage after lysis 45
Abnormal granularity (SSC) 45
Abnormal expression of CD45 64
Abnormal expression of CD71 73
Abnormal CD71/CD235a pattern2 64
Abnormal expression of CD235a 55
Abnormal expression of CD117 55
Abnormal expression of CD34 45
Abnormal expression of CD36 36
Abnormal expression of CD1052 36
Abnormal expression of H-ferritin 18
Abnormal expression of M-ferritin 18
1Percentage of survey participants who analyzed a given aberrancy; 2considered as
relevant finding.
Table 2. Parameters scored as aberrant in the maturing myeloid and monocytic compartment.
Granulocytes (maturing myeloid cells) %1 Monocytes %1
Decreased myeloid vs. lymphoid ratio (<1) 36 Decreased/increased as compared to lymphocytes2 45
Abnormal granularity (SSC)2 100 Abnormal granularity (SSC) 45
Abnormal expression of CD452 64 Abnormal expression of CD45 55
Asynchronous shift to the left 82 Abnormal distribution of immature/mature cells
Abnormal CD16/CD13 pattern2 82 Abnormal expression of CD332 73
Abnormal CD11b/CD13 pattern2 73 Expression of HLA-DR 73
Abnormal expression of CD33 73 Abnormal CD11b/HLA-DR pattern2 73
Expression of CD342 73 Expression of CD34 73
Expression of HLA-DR 73 Abnormal expression of CD14 73
Abnormal expression of CD15 55 Abnormal expression of CD132 73
Abnormal/lack of expression of CD10 45 Abnormal expression of CD362 45
Abnormal expression of CD36 45 Abnormal expression of CD64 36
Abnormal expression of CD642 36 Abnormal expression of CD11c 18
Abnormal expression of CD66 27 Abnormal expression of CD15 9
Abnormal expression of CD16 9
Expression of lineage infidelity marker CD22 73 Expression of lineage infidelity marker CD22 73
Expression of lineage infidelity marker CD5 73 Expression of lineage infidelity marker CD52 73
Expression of lineage infidelity marker CD72 82 Expression of lineage infidelity marker CD72 73
Expression of lineage infidelity marker CD192 82 Expression of lineage infidelity marker CD192 73
Overexpression of CD56 45 Overexpression of CD562 91
1percentage of survey participants who analyzed a given aberrancy; 2considered as relevant finding.
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Recommended combinations of monoclonal
antibodies
A simple and robust set of markers to analyze dyspla-
sia in the erythroid and myeloid lineages is desirable. A
minimal panel for FCM analysis of MDS should allow
the analysis of abnormal expression of selected antigens
and the relation between antigens of relevance in specif-
ic subpopulations of cells. A 4-color panel is recom-
mended in multicenter studies. A panel larger than 4-col-
ors is currently regarded as being too technically and
analytically challenging for standard clinical analysis of
MDS bone marrow samples in daily clinical practice in
all centers. Table 4 summarizes recommended antibody
combinations in which consensus could be reached,
CD45 being ubiquitous in every combination.
Experience of workshop participants and data from the
literature were helpful in deciding which of the parame-
ters would be most informative and important in the
FCM analysis of MDS. An example of a 4-color antibody
panel for FCM in MDS is shown in Table 5.
Recommended antibody combinations per specific sub-
population will be discussed below. 
Analysis of immature myeloid and lymphoid 
compartment (myeloblasts and lymphoblasts)
Definition and enumeration of blasts
The combination of CD45 and SSC provides a means to
identify myeloblasts (CD45dim and SSClow/int).36 The blasts
observed in MDS are usually restricted to this region;
however, maturation along the monocytic or neutrophilic
lineages may place the abnormal blasts outside this region.
Occasionally, abnormal myeloblasts in MDS can lack
CD45 expression altogether.37 The region where
myeloblasts reside by CD45/SSC includes not only
myeloblasts, but B-cell precursors (lymphoblasts or
hematogones), monoblasts, basophils, erythroblasts, den-
dritic cell precursors, and hematopoietic stem cells (HSC)
in varying proportions. The myeloblasts present in MDS
should be distinguished from these other populations
upon analysis by proper gating strategies using antibody
combinations such as CD45/CD34/CD117/HLA-DR and
CD45/CD34/CD123/HLA-DR.
The enumeration of blasts may be of critical impor-
tance, though there is a caveat about sample quality.
Differences are seen in blast counts as assessed by mor-
phology and FCM. Bone marrow aspirates for FCM
analysis often contain fewer bone marrow spicules than
the fraction used to prepare smears. Moreover, samples
can be diluted by peripheral blood.38 Another important
issue is the terminology of what constitutes a blast: the
definition of blasts by FCM (myeloid as well as lym-
phoid), inclusion or exclusion of granular blasts, and the
resemblance of monocytes and blasts should be defined
and/or corrected in a uniform manner.3 Myeloblasts may
Flow cytometry in MDS
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Table 4. Proposed marker combinations for flow cytometry analysis of dysplasia in myelodysplastic syndromes.*
Erythroid Immature Immature Maturing Monocytes Mature
myeloid lymphoid granulocytes lymphoid
CD71, CD235a, CD117 X
CD105 (x)
CD34,CD117 (x) X
CD11b, CD117 X
CD11b, HLA-DR X X X
CD117, HLA-DR X
CD123, HLA-DR (x)† (x)‡
CD34, CD15 X X
CD34, CD5 X X X
CD34, CD7, (CD13§) X X X
CD34, CD56 X X X
CD34, CD19 X X X X
CD10, CD19 (x) X
CD10, CD38 (x)
CD11b, CD13, CD16 X
CD65 (x)
CD64, CD14 X
CD64, CD36 (x)
CD33, CD14 X X X
CD33, CD36 (x) CD36 X X
TdT (x) (x)
CD79a (x)
CD19 κ,λ (x)**
CD3, CD4, CD8 (x)**
*CD45 is ubiquitous in every combination.X: minimally required, (x): supplementary. †Analysis of plasmacytoid DC (precursors), ‡analysis of basophils,
§CD7 expression on myeloblasts can be normal, e.g.monocytic/dendritic precursors are CD13dim/CD7dim,**to complete immunological differential.
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be defined as CD45dimSSClowCD34+ (in combination with a
myeloid marker, negative for lymphoid markers) and
denotes the earliest stage of the myeloblast. The most
mature myeloblast in normal bone marrow expresses
HLA-DR and CD117 in addition to CD34. The CD34 anti-
gen is expressed on all hematopoietic precursors, but is
lost relatively early in the maturation of hematopoietic
cells. The level of CD34 expression is highly dependent on
the CD34 antibody used since there are three different
epitopes of the CD34 antigen, and on the fluorochrome
coupled to the antibody.3 Due to the variability of the
myeloblast position in CD45/SSC plots and the hetero-
geneity of the CD34 positive fraction, multiple or redun-
dant methods are applied to identify and count the
myeloblast cells present and to analyze aberrancies on
blast cells. The percentages of myeloblasts obtained with
redundant antibodies should correlate, unless the aberrant
myeloblasts lack a particular antigen. An important caveat
is that myeloblasts in MDS can be CD34 negative.
Therefore, simply counting CD34 positive cells may be
inappropriate in studies of this disease. If cells are CD34
negative, CD117 can be chosen as an alternative progeni-
tor-marker, and myeloblasts can be defined as CD45dim
SSClow/intHLA–DR+CD11b–. The most accurate method to
enumerate myeloblasts by FCM requires elimination of
the erythroid cells in the analysis, e.g. by electronically
gating them out. Therefore, the denominator will be total
non-erythroid cells. Flow cytometry in MDS should not
be considered an analysis to exactly replicate myeloblast
counts by morphology. The cut-off level for abnormally
increased blast counts by FCM in MDS may be closer to
3% of total nucleated cells in contrast to the 5% currently
used by morphology.4,6,35,39 In addition, the detection and
enumeration of circulating (aberrant) blasts is of increasing
interest since some data suggest that the presence of blasts
in peripheral blood in RA+/-RS may influence OS or may
be associated with an increased risk of leukemic transfor-
mation and post-transplant relapse.5,40,41 The effect of sec-
ondary myelofibrosis, which may an independent risk fac-
tor, on the presence of circulating blasts or myeloid pro-
genitor cells is not yet clear. Circulating blasts in myelofi-
brosis are part of the natural course of the disease. Within
the current WHO proposal of 2008, the presence of circu-
lating blasts is discussed and seems to be associated with
a worse clinical outcome, with overall survival identical to
patients with MDS RAEB-1.5,40,41
Since a decreased percentage of progenitor B cells is fre-
quently observed in MDS, enumeration of progenitor B
cells, identified in the CD45dim/lowSSClow region and by their
CD34+CD19+CD10+ phenotype, is recommended as a use-
ful parameter.6,7,42,43 The relevance of this observation is not
yet known, since a decrease in progenitor B cells is also
seen in the elderly population without MDS and may be a
non-specific finding in other diseases such as myeloprolif-
erative disorders (MPD) and immunodeficiencies.
Recently, it was reported that, unlike CMML and MDS
patients, most MPD patients maintained an adequate B-
cell development except for those with chronic myeloid
leukemia (CML).44,45 To circumvent problems regarding
hemodilution in the enumeration of progenitor B cells, it
was recommended that these cells are expressed as a frac-
tion of all (CD34+) blast cells.39
Identification of flow cytometry aberrancies in blasts
Neoplastic myeloblasts in MDS may have an aberrant
phenotype that distinguishes them from normal blasts.
The most widely recognized aberrancies in the immature
myeloid compartment in MDS, next to an increased per-
centage, concern abnormal intensity of CD34, CD45,
Table 5. Example of a screening panel for 4-color flow cytometry of
dysplasia in myelodysplastic syndromes.
FL-1 FL-2 FL-3 FL-4
1 CD45
2 CD71 CD235a CD45 CD117
3 CD36 CD64 CD45 CD14
4 CD10 CD33 CD45 CD14
5 CD16 CD13 CD45 CD11b
6 HLA-DR CD117 CD45 CD11b
7 CD13+CD33 CD117 CD45 CD34
8 CD13 CD7 CD45 CD34
9 CD2 CD56 CD45 CD34
10 CD5 CD19 CD45 CD34
11 CD15 CD11b CD45 CD34
This panel was modified from a panel defined by the Dutch working party “FCM in
MDS”of the Dutch Society for Cytometry (NVC). It should be of note that the con-
struction of a panel depends on the available fluorochrome conjugates,antibodies
and instrument performance characteristics.
Table 6. Proposed list of pathological controls to determine the specificity of flow cytometry aberrancies in myelodysplastic syndromes.
AML, hypoplastic AML, CML,
Chronic myeloproliferative disease (e.g. PV, ET),
Aplastic anemia, PNH,
Myelofibrosis (p/s MPD and/or MDS), systemic mastocytosis, chronic eosinophilic leukemia
Langerhans cell histiocytosis, hemaphagocytosis, anemia of
Chronic diseases, anemia in autoimmune diseases (AITP, Rheumatoid Arthritis, SLE, SS), anemia due to renal insufficiency
Secondary MDS, post-chemotherapy, drugs interfering with angiogenesis,
Post-stem cell transplant settings (autologous or allogeneic stem cell Tx)
AML: acute myeloid leukemia; CML: chronic myeloid leukemia; PV: polycythemia vera; ET: essential thrombocytosis; PNH: paroxysmal nocturnal hemoglobinuria; MPD: myelo-
proliferative disorders;AITP: autoimmune thrombocytopenic purpura; SLE: systemic lupus erythematosus; SS: Sjögren syndrome; MDS: myelodysplastic syndromes.
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CD13 or CD33 and/or the expression of lineage infidelity
markers, as discussed below.4,6,8,11,35,46-48 Aberrancies evaluat-
ed by the participants of the workshop are listed in Table
1. The consensus group regarded the following features of
progenitor cells as most relevant: an increased percentage
of myeloblasts, abnormal granularity (SSC), abnormal
intensity of CD45, CD34, or CD117, or expression of
CD11b or CD15, abnormal intensity (or lack) of HLA-DR
and the expression of lineage infidelity markers such as
TdT, CD7, CD19 or CD56. CD7 can be expressed on a
small subset of early, normal myeloblasts. Antibody com-
binations that enable detection of these parameters are
included in Table 4. To ensure that lineage infidelity mark-
ers are expressed on myeloblasts, a myeloid marker such
as CD13 or CD33 can be added in the antibody combina-
tion. One must also take into account that certain aberran-
cies may appear following growth factor stimulation or
regeneration, such as expression of CD56.4,49
Analysis of the maturing myeloid and monocytic
compartment
Definition of and aberrancies in the maturing myeloid
compartment
Maturing neutrophils, hereafter referred to as granulo-
cytes, are most often defined by their CD45 expression
(intermediate)36 and SSC profile (bright); CD33 may be
added to distinguish granulocytes from monocytes in case
of overlapping populations (dim and bright expression of
CD33, respectively). Hypogranularity of granulocytes is a
well-known phenomenon in MDS.46 Hence, an abnormal
SSC is amongst the most frequently observed FCM aber-
rancies within this compartment.3 SSC of granulocytes is
often expressed as ratio relative to that obtained for lym-
phocytes. Abnormal granulocytes can also be recognized
by aberrant expression of antigens. This includes an
altered expression, e.g. an increased or decreased expres-
sion of CD45, CD13, CD33, CD11b, CD16, and CD64,
lack of CD10 on mature granulocytes, expression of CD34
or CD14, and expression of the lineage infidelity markers
CD2, CD7 or CD19.4,6,11,46-48,50 Due to genetic polymor-
phisms the expression of some antigens, e.g. CD33, may
be non-specifically decreased. Aberrant expression of such
antigens should be interpreted in relation to other myeloid
subsets as well as related to extensive normal and patho-
logical bone marrow samples.
Evaluation of aberrancies may be hampered by con-
tamination of the population of interest. For instance,
when the SSC of neutrophils is low, granulocytes often
overlap monocytes; these cells should be electronically
excluded by monocyte specific antigens such as CD14,
CD36 and CD33hi. Eosinophils should be excluded as
well; this can be done by an additional gate on CD45,
SSC and/or CD16. Loss of CD16 is observed in paroxys-
mal nocturnal hemoglobinuria (PNH) and in patients
with a genetic polymorphism.51-53 Loss of CD16 has also
been reported to coincide with apoptosis, at least in cell
culture.54 It must also be taken into account that use of
the anticoagulant EDTA may influence the expression of
certain calcium dependent antigens, e.g. CD11b, and that
cell activation can induce increased expression of HLA-
DR and CD64, if samples are not prepared rapidly and
certain antibody clones are used.3,11,32 Therefore,
immunophenotypic differences from normal patterns
may not be specific for MDS. 
Definition of and aberrancies in the monocytic compartment
Monocytes can be defined based on their CD45 expres-
sion (intermediate-bright)36 and SSC (intermediate); addi-
tional markers are CD36, CD14, CD64 and CD33. The
proportion of monocytes in a sample can be expressed as
ratio to the total non-erythroid cells or to lymphocytes. It
was recommended to quantify monocytes not only by
CD14 alone but also by CD36 and CD64, since the use of
CD14 alone may underestimate the percentage of mono-
cytes, particularly if immature forms are present.
The following aberrancies in maturing monocytes are
considered as relevant: decreased or increased proportion
of monocytes as compared to lymphocytes, abnormal
intensity of CD13 or CD33, an abnormal CD11b/HLA-
DR pattern, abnormal intensity of CD14, CD36 or CD64,
overexpression of CD56 and expression of lineage infi-
delity markers CD2, CD7 or CD19 (Table 2).4,6,11,46-48,50 As
noted above, granulocytes with a decreased SSC can
interfere in the analysis of monocytic aberrancies. It
should be noted that the adhesion molecule CD56 is not
truly a lineage infidelity marker since it can be expressed
on either lymphoid or myeloid cells; only overexpression
(>1 log) is considered as aberrant.4,49 CD56 is frequently
seen in regenerating bone marrow after chemotherapy or
stem cell transplant, on granulocytes and monocytes dur-
ing G-CSF primed stem cell collections and during infec-
tions.4,49,55,56 Nevertheless, it was recently reported that
CD56 expression on monocytes was the only discrimi-
nating marker between chronic myelomonocytic
leukemia (CMML) and MDS (p=0.007); differences relat-
ing to CD56 expression were even more significant
between CMML and MPD (p=0.0002).45 In addition, dif-
ferential expression of IREM2 and CD14 might distin-
guish between normal and leukemic monocytes; in a nor-
mal differentiation route CD14 is expressed before
IREM2, while in some leukemic monocytes IREM2 pre-
cedes CD14.57 However, additional studies are needed to
confirm this observation. 
Antibody combinations to enable analysis of aberran-
cies on granulocytes and monocytes as discussed above
are presented in Table 4.
Erythroid compartment 
Flow cytometry patterns of normal erythroid develop-
ment were originally described in 1987.58 Based on the
knowledge of normal patterns, FCM aberrancies in the
erythroid lineage in MDS were also reported in 2001.46 At
present, only limited numbers of antibodies are available
to study erythroid dysplasia, therefore the spectrum of
abnormalities in the erythroid compartment cannot be
fully assessed. The erythroid population can be defined
by lack of CD45 expression and light scatter.58 The
expression profile of glycophorin A (CD235a) and CD71
within this subpopulation is most widely analyzed. For
immature erythropoietic cells, endoglin (CD105) and
CD117 as well as CD36 can be employed as markers in
normal marrow and probably also in MDS.7,35 Analysis of
the expression of CD105 and CD117 may thus also help
in the assessment of erythroid dysplasia in MDS,
Flow cytometry in MDS
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although this has not been formally established. In addi-
tion, assessment of intracellular expression of H-ferritin
and M-ferritin (MtF) may add information on erythroid
dysplasia. M-ferritin expression is closely related to the
presence of ringed sideroblasts in bone marrow (98% sen-
sitivity, 100% specificity); and a strong correlation
between MtF and Perls staining was reported (r=0.89).59
However, these antibodies are not commercially available
at present. Consensus has been reached that at least the
expression of CD45, CD71, CD235a, CD117 and CD105
should be analyzed with emphasis on an abnormal pat-
tern of CD71 in relation to CD235a (Table 3).
Validation of specificity of flow cytometry analysis
in myelodysplastic syndromes
In addition to consensus on antibody combinations,
agreement on interpretation of antigen expression profiles
and expression patterns is necessary to enable solid infor-
mation on diagnosis, prognosis and treatment monitoring
in MDS. Multi-variate analysis of retrospective data-sets
may clarify what is important to analyze and how to eval-
uate the abnormalities for prognosis. 
To provide additional insights in the specificity and
sensitivity of the observations in MDS with respect to
controls, all aberrancies should ideally be analyzed versus
(age-matched) normal and pathological controls of
benign, stressed marrows and malignant hematologic dis-
eases. A list of proposed controls is depicted in Table 6.
Using this approach more insights will be gained dealing
with disease-specific FCM aberrancies. To illustrate the
issue of specificity: in case of hypogranularity, other dis-
orders have to be ruled out. For instance, as a stressed
bone marrow recovers the neutrophils reappear as
hypogranular, illustrating the importance of obtaining
concurrent clinical data. Further prospective (preferably
multi-center) studies need to be completed to address
these issues, and to learn what aberrancies are indeed
MDS-related or even MDS-specific. Sensitivity of the
method is another issue that raises many questions. How
many cells in a defined cellular compartment are aber-
rant? Can FCM help in cases in which cytological analy-
sis detects e.g. 9% dysplasia in one or more lineages?
Moreover, MDS is a clonal disease; a small clone may not
be recognizable since intramedullary apoptosis of progen-
itor cells may hamper appropriate detection, specially in
low-risk MDS.
Future directions for flow cytometry 
in myelodysplastic syndromes
Flow cytometry data analysis is a complex issue and con-
sensus has not yet been reached. The inherent variability
of instrument set-up and standardization can give signifi-
cant differences in the data collected between and within
institutions. Similarly, differences in reagents, especially
the fluorochromes used, will result in inconsistent sensitiv-
ity and specificity of data. Definitions must be generated
that are explicit for what is considered normal or aberrant.
Several flow scoring systems have been validated that dis-
tinguish MDS from reactive/normal controls.4,7,11,35,47,50,60 The
type of FCM analysis may be particular to any given insti-
tution and still remains valid. Several points of discussion
remain.
• Analysis of the number of aberrancies in multicenter
studies requires definition of a fixed number of aberrancies
to be scored. 
• In case of aberrancy (altered expression or altered pat-
terns of antigen expression) the degree of deviation from
normal has to be defined. In some laboratories, compari-
son of percentage or mean fluorescence intensity of indi-
vidual antigens with normal controls has been applied.7,35
Difference from normal can be described as >0.5 log, 1 log,
2 log or as >1SD, >2SD, or >3SD. This allows ranking of
the aberrancy in a relatively simple way. However, this
analysis is dependent on a confidence interval of expres-
sion of antigens on reference normal samples for each insti-
tute. Matarraz et al. showed in this way that FCM was able
to discriminate between normal or reactive bone marrow
samples and MDS cases; their scoring system even dis-
criminated low- and high-grade MDS patients.7,35
• The interpretation of expression patterns, i.e. the rela-
tion between two individual antigens, can be definitive or
equivocal. A calculation of the degree of deviation from a
normal pattern might improve evaluation. Currently, soft-
ware programs are available that can merge numerous nor-
mal expression patterns. MDS samples could, therefore, be
compared to normal samples and the program might be
able to compute the deviation from normal, not only for
individual antigens but probably even for a pattern.61,62
• Lineage infidelity marker expression may differ
between blasts, granulocytes and monocytes. Clearly
abnormal expression of certain antigens must take into
account autofluorescence of each individual cellular com-
partment.
• Weighing of aberrant parameters in the design of an
FCM scoring system must be clinically driven. This can be
determined based on parameters from retrospective data
(multivariate analysis). Some abnormalities may be
informative for diagnosis, while others for prognosis. 
Expression of lineage infidelity markers on (im)mature
myeloid or monocytic cells might carry more weight than
altered expression of myeloid and monocytic antigens and
has been used in scoring systems for outcome.4 For
instance, expression of CD7 on myeloblasts was shown to
correlate with poor clinical outcome, and CD15 expression
on myeloblasts was associated with good prognosis.6,8,9
Another issue related to interpretation of data regards the
minimal number of abnormalities by FCM necessary to
diagnose a patient as having MDS. The presence of multi-
ple aberrancies has a higher predictive value for MDS than
single aberrancies.4,5,21,47 The weight of a parameter in a
scoring system must be validated in a prospective study.
Of note, retrospective analysis of markers and marker
combinations can only be performed after this list has been
defined. 
Conclusions
Flow cytometry is an increasingly important technol-
ogy in the diagnosis and prognostication of hematopoi-
etic neoplasms. In MDS, FCM is also regarded as a new
forthcoming standard, although several questions
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remain to be solved. The consensus working group has
started to address these issues in Amsterdam, and made
significant progress in proposing standards for adequate
sampling and processing of bone marrow cells for FCM.
In addition, the group proposed antibody combinations
to define dysplasia as well as diagnostic and prognostic
FCM patterns. The group also concluded that FCM
reports should always be descriptive in nature, with a
statement that findings could be consistent with MDS.
The working group is dedicated to initiate further stud-
ies to establish commonly accepted standards and to
establish robust diagnostic and prognostic markers and
marker-patterns in MDS, with the ultimate goal being
to refine/improve diagnosis and prognostic scoring sys-
tems.
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